Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BRKR 
Bruker Corporation (BRKR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: BRKR (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $46.73
1 Year Target Price $46.73
| 5 | Strong Buy |
| 2 | Buy |
| 7 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 7.11% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/29/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.16B USD | Price to earnings Ratio 65.35 | 1Y Target Price 46.73 |
Price to earnings Ratio 65.35 | 1Y Target Price 46.73 | ||
Volume (30-day avg) 14 | Beta 1.16 | 52 Weeks Range 30.00 - 72.70 | Updated Date 08/30/2025 |
52 Weeks Range 30.00 - 72.70 | Updated Date 08/30/2025 | ||
Dividends yield (FY) 0.60% | Basic EPS (TTM) 0.52 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-04 | When - | Estimate 0.42 | Actual 0.32 |
Profitability
Profit Margin 2.31% | Operating Margin (TTM) 3.61% |
Management Effectiveness
Return on Assets (TTM) 3.55% | Return on Equity (TTM) 4.07% |
Valuation
Trailing PE 65.35 | Forward PE 17.33 | Enterprise Value 7498724022 | Price to Sales(TTM) 1.5 |
Enterprise Value 7498724022 | Price to Sales(TTM) 1.5 | ||
Enterprise Value to Revenue 2.24 | Enterprise Value to EBITDA 18.59 | Shares Outstanding 151719008 | Shares Floating 103140342 |
Shares Outstanding 151719008 | Shares Floating 103140342 | ||
Percent Insiders 31.98 | Percent Institutions 84.35 |
Upturn AI SWOT
Bruker Corporation
Company Overview
History and Background
Founded in 1960, Bruker Corporation has evolved from a German manufacturer of electromagnets to a global leader in high-performance scientific instruments and solutions for molecular and materials research.
Core Business Areas
- Bruker BioSpin Group: Develops, manufactures, and distributes NMR (Nuclear Magnetic Resonance), EPR (Electron Paramagnetic Resonance) and preclinical MRI (Magnetic Resonance Imaging) instruments.
- Bruker CALID Group: Offers mass spectrometry and chromatography systems and solutions for life science, clinical, industrial, and applied markets.
- Bruker NANO Group: Provides advanced X-ray instruments, atomic force microscopy (AFM), optical microscopy, and stylus profilers for materials research, semiconductor, and industrial applications.
Leadership and Structure
Bruker Corporation is led by CEO Frank H. Laukien. The company operates with a decentralized structure based on its core business segments.
Top Products and Market Share
Key Offerings
- NMR Spectrometers: Bruker's NMR spectrometers are used for chemical and structural analysis. Market share is estimated around 60%. Competitors include Thermo Fisher Scientific and Agilent Technologies. Significant revenue stream but no specific number is available.
- Mass Spectrometers: Bruker's mass spectrometers are employed in proteomics, metabolomics, and applied markets. Market share estimated at 20%. Competitors include Thermo Fisher Scientific, Waters Corporation, and Agilent Technologies. Significant revenue stream but no specific number is available.
- Atomic Force Microscopes (AFM): Bruker's AFMs are used for nanoscale imaging and materials characterization. Competitors include Oxford Instruments, and Park Systems.Significant revenue stream but no specific number is available.
Market Dynamics
Industry Overview
The analytical instrument market is driven by increasing research and development spending, growing demand for advanced analytical techniques, and stringent regulatory requirements.
Positioning
Bruker is a leading player in the analytical instrument market, known for its high-performance products, technological innovation, and strong brand reputation.
Total Addressable Market (TAM)
The analytical and scientific instrument market is estimated to be around $75 billion. Bruker is well-positioned within this TAM with strong presence across its product segments.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Technological innovation
- Diverse product portfolio
- Global presence
- High barriers to entry
Weaknesses
- High product costs
- Dependence on R&D spending
- Complex sales process
- Integration risks from acquisitions
Opportunities
- Growing demand for analytical instruments in emerging markets
- Increasing adoption of advanced analytical techniques
- Strategic acquisitions to expand product portfolio
- Partnerships with research institutions
- Market expansion into adjacent segments
Threats
- Intense competition
- Economic downturns
- Technological obsolescence
- Regulatory changes
- Currency fluctuations
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Agilent Technologies (A)
- Waters Corporation (WAT)
Competitive Landscape
Bruker competes with larger and more diversified companies like Thermo Fisher and Agilent. Its competitive advantage lies in its specialization in high-performance instruments and innovation. They focus less on the high-volume side of the markets, a key advantage.
Major Acquisitions
ProSpectro Holding GmbH
- Year: 2023
- Acquisition Price (USD millions): Undisclosed
- Strategic Rationale: Enhances Bruker's MALDI Imaging capabilities.
Growth Trajectory and Initiatives
Historical Growth: Bruker has demonstrated consistent revenue growth through organic expansion and strategic acquisitions.
Future Projections: Analysts project continued revenue growth driven by demand for analytical instruments and solutions.
Recent Initiatives: Bruker has been focused on strategic acquisitions to expand its product portfolio and market reach.
Summary
Bruker Corporation is a strong player in the analytical instrument market, driven by its technological innovation and strong brand reputation. Its focus on high-performance instruments gives it a competitive edge, but high product costs and R&D dependence pose challenges. Strategic acquisitions and expansion into emerging markets are key to future growth, while competition and economic downturns remain potential threats.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bruker Corporation
Exchange NASDAQ | Headquaters Billerica, MA, United States | ||
IPO Launch date 2000-08-04 | Chairman, CEO & President Dr. Frank H. Laukien Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 11396 | Website https://www.bruker.com |
Full time employees 11396 | Website https://www.bruker.com | ||
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper platform for bacterial and fungal identification and establish, DNA test strips, and; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was founded in 1960 and is headquartered in Billerica, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.